Exubrion Therapeutics® Leadership—
The Exubrion Therapeutics® Team
A seasoned team of managers and directors
Our leadership team brings a broad range of experience in various disciplines, including animal health and nuclear medicine
Peter B. Selover, BS, MIBS
Chief Executive Officer
Peter (“Pete”) leads the Exubrion team with 25 years of experience in human and animal health, having served as VP, Corporate Development & Strategy for Merial Ltd. and as Principal at Oriole Advisors, a consulting and venture firm that provides strategy and product and business development advice to new and growing animal health businesses.
He holds a BS in Electrical Engineering from Purdue University and a Master of International Business Studies from the University of South Carolina.
Some of Pete’s favorite pets have included Muffett, a loveable collie mix, and Motorola, a friendly tabby cat.
“I expect to develop novel products that enhance the quality of life and restore the natural exuberance we all cherish in our pets.”
John M. Donecker, VMD, MS
Chief Veterinary Officer
John (“Jay”) serves as the Exubrion veterinary lead, bringing with him a 40-year history in veterinary medicine, including serving as a practicing veterinarian and partner in a mixed veterinary practice for 20 years, then as Veterinary Consultant, Technical Services and Outcomes Research Veterinarian, for Pfizer Animal Health/Zoetis.
He holds a VMD from the University of Pennsylvania School of Veterinary Medicine and completed his internship at the University of Saskatchewan and residency at The Ohio State University, and earned a Masters in Clinical Sciences–Pharmacology.
A lifelong pet parent, Jay’s most notable pets over the years have included Coach Hanover, an amazing Standardbred racehorse; Jigs, a domestic short-haired cat; Bimbo, a rescue border collie mix; Noel, a foundling border collie mix; and Tilly, a beloved yellow lab.
“I became a veterinarian to make a difference in the treatment and care of animals. Helping to bring Synovetin OA® to the veterinary market is my dream coming true.”
Steven M. Fox, MS, DVM, MBA, PhD
Senior Veterinary Consultant
Steve is an integral consulting member of the Exubrion team. His wealth of experience in veterinary medicine includes over 30 years as a practicing orthopedic surgeon and pain management specialist. He also served as President of the Veterinary Orthopedic Society (VOS) and Securos Surgical. He has many years of experience in analgesic research and development, teaching, and public speaking.
He holds a BS in mechanical engineering from the US Naval Academy and an MS in nutritional biochemistry and DVM from the University of Illinois. He completed his internship at Rowley Memorial Hospital and surgical residency at the University of Florida. In addition, he holds an MBA and a PhD in pain management; both from Massey University in New Zealand.
Steve is the pet parent of 3 Siamese cats: Jasmine, Winston, and Ramsey, as well as 2 dogs: Lacey, a golden retriever, and Te’a, an English cream golden retriever.
“In human medicine, pain is what the patient says it is. In veterinary medicine, pain is what the observer says it is. ‘When in doubt: treat!’”
Anita Jarrard, BS
Executive Administrative Assistant
Anita leads the organizational functions at Exubrion and brings over 25 years of executive administration experience to the team. Prior to joining Exubrion, she spent 23 years in the big data industry working with top executives at Equifax and LexisNexis.
She holds a BS in business management from the University of Georgia.
Anita is the pet parent of a 6-lb. teacup Yorkie named Trixie, whom she is happy to let rule the home.
“My father instilled the words of Arthur Schopenhauer in my heart: ‘Compassion for animals is intimately associated with goodness of character, and it may be confidently asserted that he who is cruel to animals cannot be a good man.’”
Martin P. Manco, BS, MBA, JD
Secretary and Chief Financial Officer
Martin (“Marty”) managed the legal aspects of founding Exubrion. Along with the Chief Veterinary Officer, he was involved in the business aspects of the canine clinical trial program and managed the financial and legal affairs of the company and Serene LLC, its parent.
Marty has a BS in Economics from The Wharton School of the University of Pennsylvania, an MBA from The Pennsylvania State University, and a JD from Widener University School of Law.
In addition, Marty is licensed to practice law in and has a Post-Masters Certificate in Management Information.
“Relieving the pain and suffering of family pets contributes to the quality of life of the entire family. This gives me great pleasure and satisfaction.”
Eric Schreiber, BSBA
Chief Marketing Officer
Eric heads up marketing, advertising, and sales at Exubrion, bringing 30 years of experience in these disciplines to the team.
He holds a BS in Business Administration from Bucknell University and has completed executive education programs at Wharton and Kellogg.
Eric is the pet parent of Xander, an English Labrador retriever.
“I thrive on the excitement of bringing new technologies to market and seeing their effect on improving the quality of life for pets, pet parents, and veterinarians.”
Nigel Stevenson, BSc, PhD
Chief Operating Officer
Nigel works as the operations lead at Exubrion and brings a long history in physics, nuclear physics, and radioisotope research and development to the role. Nigel has held senior positions in several radioisotope manufacturing and research companies in addition to academic roles at National Laboratories. He has over 90 publications and more than 30 patents in this field. He is the Immediate Past President of the World Council on Isotopes.
Nigel holds a BSc in physics and a PhD in nuclear physics from The University of London, U.K.
Nigel is the pet parent of Chanel, Zoe, and Angel, all Pomeranians, his most recent of many beloved dogs.
“As a lifelong dog parent, I sympathize with dogs that suffer from painful conditions and strongly desire to provide a solution that alleviates this.”
Tim works as the production manager for Exubrion Therapeutics and brings over 25 years of manufacturing experience in the medical device and pharmaceutical industries to the team.
Tim holds a BS in Biochemistry and Chemistry from the University of Georgia.
Tim is the pet parent to 2 dogs: Hank and Dolly, litter mates that are a Chihuahua mix, as well as a cat: Kixie, a yellow tabby.
“I was taught at an early age that my pets' welfare came first. If I was hungry and thirsty, I fed and watered my pets before I ate or drank. It excites me to know that we are providing pain relief to animals that do not understand their pain.”
Jackie Lynn Stone, BA
Jackie is a key account manager for Exubrion. She brings over 30 years of experience in veterinary medicine to the role, having worked as a critical care vet tech and as a product specialist for orthopedic implants and biologics.
She holds a BA in psychology with an emphasis in behavioral neuroscience from California State University, Northridge.
Jackie is the pet parent of Jinjee Lynn, a golden retriever.
“Patient outcomes are my #1 priority. I feel blessed to be part of the process of patient care by supporting the many veterinarians I interact with.”
Wes Woods, BS
Wes Woods is the Austin, TX based Key Account Manager for Exubrion Therapeutics®. He graduated from Texas A&M University in 2008 with a Bachelor of Science in Biomedical Sciences. Wes has been in the animal health industry for 12 years. He considers anyone in the animal health industry family.
Wes and his wife, Sarah, have 3 daughters: Hannah, Abby, and Pearl (their golden retriever).
"I couldn't be any more blessed than to introduce exciting new technologies to the animal health industry, where I was born and raised."
Synovetin OA® delivers sustained OA pain relief.1
Synovetin OA® provides targeted, non-systemic therapy.2
- Data on file, Exubrion Therapeutics®.
- Donecker JM, Fox SM. Safety and effectiveness of Synovetin OA®: Results of three randomized trials evaluating treatment of naturally occurring canine elbow osteoarthritis. Exubrion Therapeutics®, July 2019.